{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:34:00Z","timestamp":1793324040747,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018817","name":"LUPUS UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clim.2022.109028","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T20:23:19Z","timestamp":1651522999000},"page":"109028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study"],"prefix":"10.1016","volume":"239","author":[{"given":"Eve M.D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Egbivwie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam","family":"Al-Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Armon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Gardner-Medwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulshan","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"McLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Pilkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyapal","family":"Rangaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arani","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Hedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2022.109028_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108274","article-title":"Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options","volume":"209","author":"Smith","year":"2019","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2022.109028_bb0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.berh.2018.02.001","article-title":"Juvenile-onset systemic lupus erythematosus (jSLE) \u2013 pathophysiological concepts and treatment options","volume":"31","author":"Hedrich","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2022.109028_bb0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.10072","article-title":"Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage","volume":"46","author":"Brunner","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.clim.2022.109028_bb0020","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2022.109028_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.24091","article-title":"Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus","volume":"61","author":"Hersh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2022.109028_bb0030","author":"UK JSLE Study Group"},{"key":"10.1016\/j.clim.2022.109028_bb0035","author":"Orphanet"},{"issue":"2","key":"10.1016\/j.clim.2022.109028_bb0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.23204","article-title":"Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus","volume":"58","author":"Brunner","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2022.109028_bb0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semarthrit.2019.05.010","article-title":"Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus","volume":"49","author":"Heshin-Bekenstein","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.clim.2022.109028_bb0050","first-page":"1047","article-title":"Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)","volume":"35","author":"Torrente-Segarra","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2022.109028_bb0055","first-page":"261","article-title":"Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus","volume":"23","author":"Lilleby","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2022.109028_bb0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.11205","article-title":"Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study","volume":"49","author":"Ravelli","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"14","key":"10.1016\/j.clim.2022.109028_bb0065","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1177\/0961203316644333","article-title":"Differences in disease phenotype and severity in SLE across age groups","volume":"25","author":"Ambrose","year":"2016","journal-title":"Lupus."},{"issue":"4","key":"10.1016\/j.clim.2022.109028_bb0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1191\/0961203306lu2291oa","article-title":"Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus","volume":"15","author":"Brunner","year":"2006","journal-title":"Lupus."},{"issue":"12","key":"10.1016\/j.clim.2022.109028_bb0075","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109028_bb0080","article-title":"Diagnosis and treatment of childhood-onset systemic lupus erythematosus (European evidence-based recommendations from the SHARE initiative)","author":"Smith","year":"2018","journal-title":"Arch. Dis. Child Educ. Pract Ed"},{"issue":"3","key":"10.1016\/j.clim.2022.109028_bb0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/acr.21558","article-title":"Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus","volume":"64","author":"Mina","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2022.109028_bb0090","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). (1468\u20132060 (Electronic))."},{"issue":"2","key":"10.1016\/j.clim.2022.109028_bb0095","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2022.109028_bb0100","article-title":"\u2018It gives the treatment structure\u2019: Patient and parental perspectives on treating to target in juvenile-onset systemic lupus erythematosus treat. Proceedings of the 26th European Paediatric Rheumatology Congress: part 1","volume":"18","author":"Smith","year":"2020","journal-title":"Pediatr. Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2022.109028_bb0105","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","article-title":"European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.clim.2022.109028_bb0110","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1136\/annrheumdis-2016-211001","article-title":"European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.clim.2022.109028_bb0115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.clim.2022.109028_bb0120","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.clim.2022.109028_bb0125","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/rheumatology\/keh284","article-title":"The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus","volume":"43","author":"Marks","year":"2004","journal-title":"Rheumatology."},{"issue":"7","key":"10.1016\/j.clim.2022.109028_bb0130","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.34410","article-title":"Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort","volume":"64","author":"Watson","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"259","key":"10.1016\/j.clim.2022.109028_bb0135","first-page":"927","article-title":"Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG)","volume":"69","author":"Symmons","year":"1988","journal-title":"Q. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2022.109028_bb0140","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2022.109028_bb0145","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology."},{"issue":"3","key":"10.1016\/j.clim.2022.109028_bb0150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/rheumatology\/keh012","article-title":"Lupus nephritis: treatment with mycophenolate mofetil","volume":"43","author":"Kapitsinou","year":"2004","journal-title":"Rheumatology."},{"issue":"6","key":"10.1016\/j.clim.2022.109028_bb0155","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","volume":"6","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.clim.2022.109028_bb0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/0961203319836712","article-title":"Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis","volume":"28","author":"Smith","year":"2019","journal-title":"Lupus."},{"issue":"21","key":"10.1016\/j.clim.2022.109028_bb0165","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.clim.2022.109028_bb0170","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1177\/0961203320958055","article-title":"Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: a novel case report","volume":"29","author":"Nawata","year":"2020","journal-title":"Lupus."},{"key":"10.1016\/j.clim.2022.109028_bb0175","unstructured":"Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. (0300\u20139742 (Print))."},{"issue":"10","key":"10.1016\/j.clim.2022.109028_bb0180","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1191\/0961203305lu2163cr","article-title":"Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus","volume":"14","author":"Mak","year":"2005","journal-title":"Lupus."},{"issue":"5","key":"10.1016\/j.clim.2022.109028_bb0185","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0961203315625118","article-title":"Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil","volume":"25","author":"Tagawa","year":"2016","journal-title":"Lupus."},{"issue":"3","key":"10.1016\/j.clim.2022.109028_bb0190","first-page":"588","article-title":"Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis","volume":"34","author":"Tomietto","year":"2007","journal-title":"J. Rheumatol."},{"issue":"8","key":"10.1016\/j.clim.2022.109028_bb0195","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0961203316644339","article-title":"Organ involvement other than lupus nephritis in childhood-onset systemic lupus erythematosus","volume":"25","author":"Huggins","year":"2016","journal-title":"Lupus."},{"issue":"6","key":"10.1016\/j.clim.2022.109028_bb0200","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.clim.2022.109028_bb0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-015-0534-3","article-title":"Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives","volume":"76","author":"Magro-Checa","year":"2016","journal-title":"Drugs."},{"issue":"3","key":"10.1016\/j.clim.2022.109028_bb0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40272-016-0170-8","article-title":"pharmacological management of childhood-onset systemic lupus erythematosus","volume":"18","author":"Thorbinson","year":"2016","journal-title":"Paediatric drugs."},{"issue":"3","key":"10.1016\/j.clim.2022.109028_bb0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5487\/TR.2010.26.3.163","article-title":"Use of antioxidants to prevent cyclosporine a toxicity","volume":"26","author":"Lee","year":"2010","journal-title":"Toxicol. Res."},{"issue":"3","key":"10.1016\/j.clim.2022.109028_bb0220","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12016-016-8582-3","article-title":"The use of cyclosporine a in rheumatology: a 2016 comprehensive review","volume":"52","author":"Chighizola","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"7","key":"10.1016\/j.clim.2022.109028_bb0225","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus - past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2022.109028_bb0230","author":"England. N"},{"issue":"1","key":"10.1016\/j.clim.2022.109028_bb0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.clim.2022.109028_bb0240","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2022.109028_bb0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0961203314547793","article-title":"The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE","volume":"24","author":"Watson","year":"2015","journal-title":"Lupus."},{"key":"10.1016\/j.clim.2022.109028_bb0250","series-title":"Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]","author":"NICE","year":"2021"},{"issue":"4","key":"10.1016\/j.clim.2022.109028_bb0255","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0961203307087875","article-title":"Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)","volume":"17","author":"Tucker","year":"2008","journal-title":"Lupus."},{"key":"10.1016\/j.clim.2022.109028_bb0260","doi-asserted-by":"crossref","unstructured":"Mina R, Brunner HI. Pediatric lupus\u2013are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum. Dis. Clin. N. Am. 2010;36(1):53\u201380, vii-viii.","DOI":"10.1016\/j.rdc.2009.12.012"},{"issue":"2","key":"10.1016\/j.clim.2022.109028_bb0265","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pcl.2012.03.007","article-title":"Systemic lupus erythematosus in children and adolescents","volume":"59","author":"Levy","year":"2012","journal-title":"Pediatr. Clin. N. Am."},{"issue":"12","key":"10.1016\/j.clim.2022.109028_bb0270","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1093\/rheumatology\/keab173","article-title":"\u201cIt is good to have a target in mind\u201d: Qualitative views of patients and parents informing a treat to target clinical trial in JSLE","volume":"60","author":"Smith","year":"2021","journal-title":"Rheumatology."},{"issue":"6","key":"10.1016\/j.clim.2022.109028_bb0275","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109028_bb0280","unstructured":"Davies JC, Carlsson E, Midgley A, Smith EMD, Bruce IN, Beresford MW, et al. A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. (1462\u20130332 (Electronic))."},{"key":"10.1016\/j.clim.2022.109028_bb0285","doi-asserted-by":"crossref","unstructured":"Davies JC, Midgley A, Carlsson E, Donohue S, Bruce IN, Beresford MW, et al. Urine and serum S100A8\/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. LID - 10.1136\/rmdopen-2020-001257 [doi] LID - e001257. (2056\u20135933 (Electronic)).","DOI":"10.1136\/rmdopen-2020-001257"},{"key":"10.1016\/j.clim.2022.109028_bb0290","unstructured":"Donohue SJ, Midgley A, Davies JC, Wright RD, Bruce I, Beresford MW, et al. Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). (1521\u20137035 (Electronic))."},{"key":"10.1016\/j.clim.2022.109028_bb0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clim.2018.10.021","article-title":"A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: predicting changes in disease activity","volume":"198","author":"Smith","year":"2019","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2022.109028_bb0300","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2022.109028_bb0305","unstructured":"Bridges JA-O, Stoll MA-O. Treatment of juvenile spondyloarthritis: where we stand. (1179\u20132019 (Electronic))."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:06:25Z","timestamp":1761494785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":61,"alternative-id":["S1521661622001097"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.109028","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.109028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109028"}}